News
TOVX
0.4152
-7.32%
-0.0328
Theriva Biologics Upcoming Investor Presentations Insight
TipRanks · 3d ago
Weekly Report: what happened at TOVX last week (0408-0412)?
Weekly Report · 4d ago
THERIVA™ BIOLOGICS ANNOUNCES PRESENTATION AT THE AMERICAN SOCIETY FOR CELL AND GENE THERAPY 27TH ANNUAL MEETING
Reuters · 04/08 12:00
Weekly Report: what happened at TOVX last week (0401-0405)?
Weekly Report · 04/08 09:48
Weekly Report: what happened at TOVX last week (0325-0329)?
Weekly Report · 04/01 09:48
Buy Recommendation for Theriva Biologics Backed by Promising Oncolytic Adenovirus Platform and Clinical Trial Advancements
TipRanks · 03/27 19:05
Theriva Biologics GAAP EPS of -$1.14 beats by $0.23
Theriva Biologics, Inc. FY GAAP EPS of -$1.14 beats by $0.23. As of December 31, 2023, the company has $23.2 million in cash. The company is expected to provide runway into the first quarter of 2025.
Seeking Alpha · 03/25 12:01
Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Benzinga · 03/25 11:32
Press Release: Theriva(TM) Biologics Reports -2-
Theriva Biologics is a diversified clinical-stage company developing therapeutics to treat cancer and related diseases. The Company is advancing a new oncolytic adenovirus platform designed to trigger tumor cell death. The company's lead candidates are VCN-01 and SYN-004. This release contains forward-looking statements.
Dow Jones · 03/25 11:30
Press Release: Theriva(TM) Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
Theriva(TM) Biologics Reports Full-Year 2023 Operational Highlights and Financial Results. The independent data monitoring committee recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma. No safety concerns raised. The trial remains on track to complete enrollment in the first half of 2024. As of December 31, 2023, Theriva reports $23.2 million in cash. Conference call and webcast to be held March 25.
Dow Jones · 03/25 11:30
Weekly Report: what happened at TOVX last week (0318-0322)?
Weekly Report · 03/25 09:49
Earnings Scheduled For March 25, 2024
Bitcoin Depot is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. Syra Health is likely to report earnings for its fourth quarter. Other companies reporting before the bell and after the bell include BuzzFeed and Rekor Systems.
Benzinga · 03/25 09:33
Preview: Theriva Biologics's Earnings
Theriva Biologics is set to give its latest quarterly earnings report on Monday, 2024-03-25. Analysts estimate the company will report an earnings per share of $-0.41. Last quarter the company beat EPS by $0.18, but the share price dropped by 10.86%. Shares of the company are down 19.06% in the last 52 weeks.
Benzinga · 03/22 14:01
Theriva Biologics FY 2023 Earnings Preview
Theriva Biologics, Inc. (TOVX) is scheduled to announce FY earnings results on Monday, March 25th. The consensus EPS Estimate is -$1.15. Over the last 1 year, TOVX has beaten EPS estimates 50% of the time.
Seeking Alpha · 03/22 13:00
Theriva Biologics Granted EU Patent #3292142 For "Oncolytic Adenoviruses With Mutations In Immunodominant Adenovirus Epitopes And Their Use In Cancer Treatment"
Benzinga · 03/20 20:01
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
Theriva™ Biologics plans to host a conference call on March 25, 2024. The company will discuss its financial results for the full year ended December 31, 2023 and provide a corporate update. Theriva is developing therapeutics designed to treat cancer and related diseases.
Barchart · 03/19 07:00
Weekly Report: what happened at TOVX last week (0311-0315)?
Weekly Report · 03/18 09:48
Weekly Report: what happened at TOVX last week (0304-0308)?
Weekly Report · 03/11 09:47
Weekly Report: what happened at TOVX last week (0226-0301)?
Weekly Report · 03/04 09:48
Weekly Report: what happened at TOVX last week (0219-0223)?
Weekly Report · 02/26 09:53
More
Webull provides a variety of real-time TOVX stock news. You can receive the latest news about THERIVA BIOLOGICS INC through multiple platforms. This information may help you make smarter investment decisions.
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.